Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director Todd Foley sold 25,366 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $22.03, for a total value of $558,812.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Todd Foley also recently made the following trade(s):
- On Friday, November 29th, Todd Foley sold 18,359 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $22.67, for a total value of $416,198.53.
- On Wednesday, November 27th, Todd Foley sold 34,960 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $22.91, for a total value of $800,933.60.
- On Monday, November 25th, Todd Foley sold 121,343 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $23.16, for a total value of $2,810,303.88.
- On Friday, November 22nd, Todd Foley sold 102,682 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $21.78, for a total value of $2,236,413.96.
- On Wednesday, November 20th, Todd Foley sold 141,365 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $22.02, for a total transaction of $3,112,857.30.
NASDAQ RYTM opened at $22.40 on Wednesday. The stock has a 50-day simple moving average of $21.86 and a 200 day simple moving average of $22.14. Rhythm Pharmaceuticals Inc has a twelve month low of $18.00 and a twelve month high of $31.94. The stock has a market capitalization of $986.15 million, a PE ratio of -9.37 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.78 and a current ratio of 6.78.
RYTM has been the subject of a number of analyst reports. BidaskClub upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 22nd. Zacks Investment Research raised shares of Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Cowen reiterated a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, September 25th. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $43.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $38.80.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in Rhythm Pharmaceuticals by 24.9% during the 2nd quarter. BlackRock Inc. now owns 1,908,058 shares of the company’s stock worth $41,976,000 after acquiring an additional 380,085 shares during the period. Millennium Management LLC boosted its stake in shares of Rhythm Pharmaceuticals by 1,110.9% in the 3rd quarter. Millennium Management LLC now owns 240,428 shares of the company’s stock valued at $5,190,000 after purchasing an additional 220,573 shares in the last quarter. University of Notre Dame DU Lac bought a new stake in shares of Rhythm Pharmaceuticals during the 2nd quarter valued at approximately $3,051,000. State Street Corp grew its stake in shares of Rhythm Pharmaceuticals by 18.7% during the third quarter. State Street Corp now owns 717,540 shares of the company’s stock worth $15,492,000 after buying an additional 113,164 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Rhythm Pharmaceuticals in the 3rd quarter worth about $1,547,000. Institutional investors own 78.13% of the company’s stock.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
See Also: What is net income?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.